Please use this identifier to cite or link to this item:
Title: Vitreoretinal lymphoma
Authors: Sobolewska, Bianka
Chee, Soon-Phaik 
Zaguia, Fatma
Goldstein, Debra Anne
Smith, Justine R.
Fend, Falko
Mochizuki, Manabu
Zierhut, Manfred
Keywords: CNS lymphoma
IL-10/IL-6 ratio
Vitreoretinal lymphoma
Issue Date: 4-Aug-2021
Publisher: MDPI AG
Citation: Sobolewska, Bianka, Chee, Soon-Phaik, Zaguia, Fatma, Goldstein, Debra Anne, Smith, Justine R., Fend, Falko, Mochizuki, Manabu, Zierhut, Manfred (2021-08-04). Vitreoretinal lymphoma. Cancers 13 (16) : 3921. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year. The diagnosis of VRL is challenging due to nonspecific chronic and relapsing uveitis and is made by anterior chamber tab or vitreous aspirate biopsy. There is no established treatment protocol for VRL patients with bilateral involvement without CNS involvement. There are suggestions to use only intravitreal chemotherapy with methotrexate and/or rituximab. Alternatively, systemic high-dose MTX treatment or external beam radiotherapy is used. Further studies are needed to prove and confirm the prophylactic systemic therapy in preventing CNS involvement in limited VRL. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Cancers
ISSN: 2072-6694
DOI: 10.3390/cancers13163921
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers13163921.pdf79.4 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons